Novel N-Linked Aminopiperidine-Based Gyrase Inhibitors with Improved hERG and in Vivo Efficacy against Mycobacterium tuberculosis
Authors:
- Shahul Hameed PSPShahul Hameed P
- Vikas PatilVPVikas Patil
- Suresh SolapureSSSuresh Solapure
- Umender SharmaUSUmender Sharma
- Prashanti MadhavapeddiPMPrashanti Madhavapeddi
- Anandkumar RaichurkarARAnandkumar Raichurkar
- Murugan ChinnapattuMCMurugan Chinnapattu
- Praveena ManjrekarPMPraveena Manjrekar
- Gajanan ShanbhagGSGajanan Shanbhag
- Jayashree PutturJPJayashree Puttur
- Vikas ShindeVSVikas Shinde
- Sreenivasaiah MenasinakaiSMSreenivasaiah Menasinakai
- 23 May 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (11) , 4889-4905
Abstract
DNA gyrase is a clinically validated target for developing drugs against Mycobacterium tuberculosis (Mtb). Despite the promise of fluoroquinolones (FQs) as anti-tuberculosis drugs, the prevalence of pre-existing resistance to FQs is likely to restrict their clinical value. We describe a novel class of N-linked aminopiperidinyl alkyl quinolones and naphthyridones that kills Mtb by inhibiting the DNA gyrase activity. The mechanism of inhibition of DNA gyrase was distinct from the fluoroquinolones, as shown by their ability to inhibit the growth of fluoroquinolone-resistant Mtb. Biochemical studies demonstrated this class to exert its action via single-strand cleavage rather than double-strand cleavage, as seen with fluoroquinolones. The compounds are highly bactericidal against extracellular as well as intracellular Mtb. Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability. Compounds from this series are efficacious in various murine models of tuberculosis.Keywords
This publication has 25 references indexed in Scilit:
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialThe Lancet, 2012
- Current possibilities and unresolved issues of drug target validation inMycobacterium tuberculosisExpert Opinion on Drug Discovery, 2011
- Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG ActivityJournal of Medicinal Chemistry, 2011
- Type IIA topoisomerase inhibition by a new class of antibacterial agentsNature, 2010
- Beijing Genotype of Mycobacterium tuberculosis Is Significantly Associated with High-Level Fluoroquinolone Resistance in VietnamAntimicrobial Agents and Chemotherapy, 2009
- Crystal structure of the DNA gyrase GyrA N‐terminal domain from Mycobacterium tuberculosisProteins: Structure, Function, and Bioinformatics, 2009
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Quinolone-Mediated Bacterial DeathAntimicrobial Agents and Chemotherapy, 2008
- Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998